EurekAlert! Cancer Research - News Releases

News Releases

Updates every hour. Last Updated: 26-Oct-2026 04:16 ET (26-Oct-2026 08:16 GMT/UTC)

Alliance to showcase vital role of clinical trials in new film

Alliance for Clinical Trials in Oncology
Business Announcement

The Alliance for Clinical Trials in Oncology has released a film highlighting the critical role of participant involvement in advancing cancer research and improving care.

Pusan National University develops injectable microgels for targeted keloid radiotherapy

Pusan National University
Peer-Reviewed Publication

Researchers in Korea are developing a new approach to localized brachytherapy that could improve the treatment of keloid scars. The strategy uses injectable, biodegradable hyaluronic acid microgels that act as tiny radiation reservoirs within target tissue. By combining rapid radiolabeling with localized delivery, the platform aims to overcome limitations of conventional radiation treatment while offering greater flexibility and precision. The study highlights a promising step toward targeted, minimally invasive microbrachytherapy.

Journal: Journal of Controlled Release

Prospective multicenter study of first-line stem cell mobilization with EAP regimen in multiple myeloma and lymphoma

Chinese Medical Journals Publishing House Co., Ltd.
Peer-Reviewed Publication

This prospective multicenter phase II study evaluated optimized EAP as first-line stem cell mobilization for myeloma and lymphoma. It achieved excellent collection efficacy, acceptable hematologic toxicity, and favorable post-transplant outcomes.

Journal: Chinese Medical Journal
Funder: Zhejiang Provincial Medical and Health Science and Technology Project, Ningbo Public Welfare Science and Technology Program, Ningbo Top Medical and Health Research Program, Ningbo "Innovation Yongjiang 2035" Key Technology Breakthrough Program, Natural Science Foundation of Zhejiang Province Project

New insights into how neurosurgeon Paul Kalanithi conceptualized death while facing terminal cancer

University of Sharjah
Peer-Reviewed Publication

Researchers shed light on how Kalanithi’s acclaimed memoir portrays death as he grappled with terminal cancer following his diagnosis at the age of 36.

Journal: Language and Health

Secret sugar pairings curb abnormal cell-growth signals

Okinawa Institute of Science and Technology (OIST) Graduate University
Peer-Reviewed Publication

Acting as an armor, a scaffold, and a communication platform, the plasma membrane lies at the heart of many crucial cellular processes. Now, researchers at OIST and collaborating institutions have revealed a crucial yet often overlooked membrane component: complex sugar chains, known as glycans. They found that glycans carried by gangliosides form weak, short-lived pairs through repeated "fleeting encounters," helping build membrane nanodomains and regulate epidermal growth factor receptor (EGFR) signaling, which in turn modulates cell division.

Journal: Nature Communications
Funder: Japan Science and Technology Agency, Japan Society for the Promotion of Science, Japan Ministry of Education, Culture, Sports, Science and Technology, Japan Agency for Medical Research and Development, National Cancer Center Japan, Takeda Science Foundation, Uehara Memorial Foundation, Nakatani Foundation for Advancement of Measuring Technologies in Biomedical Engineering, Mizutani Foundation for Glycoscience

Research finds key cancer-related receptor is regulated by glycan interactions on cell surfaces

Institute for Glyco-core Research (iGCORE), Tokai National Higher Education and Research System
Peer-Reviewed Publication

When proteins and lipids interact at the cell surface, they kick off essential cellular signaling pathways that play a role in physiological processes throughout the body. When these interactions and signaling pathways are disrupted, it can create conditions where cells can grow out of control and turn into tumors or other diseases. Therefore, understanding how these molecules interact at the cell surface may help inform the development of more targeted therapies in the future. Beyond proteins and lipids, polymers made of sugars called glycans that form a layer on the cell surface also seem to play a similarly important role that has yet to be completely understood.

Journal: Nature Communications

AI-tested messages may improve awareness of alcohol-related cancer risks

University of Miami Miller School of Medicine
Peer-Reviewed Publication

A new study published in Cancer found that alcohol warnings naming specific cancers—and pairing them with AI-generated visuals—drew more attention and stronger intentions to cut back on drinking. Notably, only about one in five participants recognized alcohol as a breast cancer risk factor.

Journal: Cancer

Standard breast cancer classification may overlook important differences

Karolinska Institutet
Peer-Reviewed Publication

Breast cancer is often classified as either estrogen receptor-positive (hormone-sensitive) or not. However, a new study from Karolinska Institutet suggests that this simplified classification may overlook important biological differences between patients that could affect treatment decisions. The results are published in The Lancet Regional Health – Europe.

Journal: The Lancet Regional Health - Europe

Only 20% of men know consuming dairy products can increase prostate cancer risk, finds new survey

Physicians Committee for Responsible Medicine
Reports and Proceedings

Ahead of Prostate Cancer Awareness Month in September, a new survey finds that just 20% of men know that consuming milk and other dairy products can increase the risk of prostate cancer. After learning about the increased risk, 66% said they are likely to avoid dairy products.

FDA approves daraxonrasib for metastatic pancreatic cancer following landmark clinical trial led by Dana-Farber

Dana-Farber Cancer Institute
Reports and Proceedings

The U.S. Food and Drug Administration (FDA) has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy. The approval is based primarily on the results from the pivotal randomized phase 3 RASolute 302 trial comparing daraxonrasib to chemotherapy as second-line therapy for patients with metastatic pancreatic cancer, led by Brian Wolpin, MD, MPH, director of the Hale Family Center for Pancreatic Cancer Research at Dana-Farber Cancer Institute.

66
67
68
69
70